WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) recently announced the launch of its new online Tumor Model Compendium web interface. The new Compendium interface provides oncology researchers with an easily accessible, user-friendly resource to identify tumor models based on specific molecular and histological properties, accompanied by selected patient information.
Charles River’s Compendium provides access to a comprehensive collection of well-established tumor models for early-stage oncology research. The collection includes tumor models from a wide range of tumor subtypes for both in vivo and in vitro oncology research, including patient-derived xenografts (PDXs), cell line-derived xenografts (CDX), and syngeneic models. These resources allow researchers to easily identify the most appropriate tumor models, leading to a more targeted study design from the start, saving time and money on the path to the clinic.
Dedication to Immuno-oncology
The most recent Compendium
update expands existing content to include human leukocyte antigen (HLA)
subtyping data. As the immuno-oncology industry shifts toward
increasingly more personalized therapies, the availability of HLA data
helps researchers understand and control immune system variability,
leading to increased study efficacy and efficiency.
The Compendium is just one example of Charles River’s commitment to developing a robust offering of immuno-oncology services. In January 2018, the Company announced its acquisition of KWS BioTest, adding significant expertise in immunology to its existing portfolio.
In Vitro Oncology Services
Additionally, the
Compendium now includes new molecular data for a large proportion of its
proprietary and commercial cell lines, making it a valuable resource for in
vitro oncology research. In vitro oncology has emerged as an
industry standard for early toxicity and patient identification,
allowing researchers to test the efficacy of compound in a rapid,
reliable, and cost-effective way.
The Company has also partnered with OcellO and InSphero AG to leverage 3D cell culture technology with its existing in vitro oncology platforms. Charles River has more than 450 well-characterized, proprietary PDXs in its portfolio, which represent all major tumor histotypes, and provide extensive background and characterization for oncology research. To learn more about Charles River’s oncology research capabilities, visit www.criver.com.
Approved Quotes
- “The oncology field is rapidly changing and expanding, making it critically important for researchers to be as efficient as possible. If we can save researchers any amount of time in getting their studies started, that ultimately leads to safe and effective treatments being delivered to patients faster.” –Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Charles River
- “In oncology, there is a massive amount of information to sort through. The Tumor Model Compendium makes the data easily accessible and simple to digest, and allows scientists to select the most relevant data for their research.” –Aidan Synnott, Executive Director, Discovery Oncology, Charles River
About Charles River
Charles River provides essential
products and services to help pharmaceutical and biotechnology
companies, government agencies and leading academic institutions around
the globe accelerate their research and drug development efforts. Our
dedicated employees are focused on providing clients with exactly what
they need to improve and expedite the discovery, early-stage development
and safe manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services, visit www.criver.com.
